|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that PIG3 was involved in HIF-1α regulation, and reveal a novel signaling pathway of PIG3/HIF-1α in the regulation of cell migration in renal cell carcinoma.
|
27029070 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally changes in HIF1α and TNF signaling are highly represented by changes between high- and low-grade ccRCC.
|
26670202 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hypoxia-inducible factors HIF1α and HIF2α play a crucial role in ccRCC initiation and progression.
|
27507852 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study describes the relationship among proliferation, survival, and apoptosis with the expression of key molecules related to tumoral hypoxia (hypoxia-inducible factor (HIF)-1α, erythropoietin (EPO), vascular endothelial growth factor (VEGF)), their receptors (EPO-R, VEGFR-2), and stearoyl desaturase-1 (SCD-1) in early stages of ccRCC.
|
27468719 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we propose that concurrent activation of p53 and HIF1α may effectively result in cancer-cell apoptosis, and that combined MDM2 antagonists and mTOR inhibitors may be useful in RCC therapy.
|
26937175 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression and significance of FOXP1, HIF-1a and VEGF in renal clear cell carcinoma.
|
25778315 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies show that a constitutively active HIF1α promotes tumorigenesis in TRACK mice by mediating a metabolic switch to aerobic glycolysis, i.e., the Warburg effect, and suggest that TRACK mice are a valid model to test novel therapies targeting metabolic changes to inhibit human ccRCC.
|
25830305 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, whereas HIF1 has a tumor-suppressor role, HIF2 plays a distinct role in driving CRCC.
|
25421578 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The elucidation of the VHL-HIF-1α (hypoxia inducible factor-1α)-VEGF (vascular endothelial growth factor) pathway has led to the development of targeted therapy in renal cell carcinoma (RCC).
|
26021863 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that blockade HIF-1a and reforming energy metabolism with auraptene is an effective approach for suspension RCC progression.
|
26474388 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that HIF-1α-dependent inflammation and fibrosis may be an early event in the development of ccRCC.
|
25023703 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the effect of SF1126 on hypoxic HIF-1α/HIF-2α stability as well as on antitumor and/or antiangiogenic activity in renal cell carcinoma (RCC) models in vitro and in vivo.
|
25578041 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to determine the effect of variation within microRNA (miRNA)-binding sites of genes in the VHL-HIF1α pathway on RCC risk.
|
22517515 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many publications do not support a tumor suppressor role for HIF1α in ccRCC.
|
24916472 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum Ang-2 and MMP-2 and tumor HIF-1α were identified as relevant baseline biomarkers of sunitinib activity in advanced RCC, warranting further research into their prognostic versus predictive value.
|
25100134 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study analyzes the impact of genetic alterations and protein expression of VHL and the C1772T SNP of HIF-1α gene (HIF-1α) on prognosis in early-stage ccRCC (pT1a, pT1b, and pT2).
|
24446253 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that HAVCR/KIM-1 activates the IL-6/STAT-3/HIF-1A axis in ccRCC-derived cell lines, which depends on HAVCR/KIM-1 shedding.
|
24390735 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
|
23273913 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MOTIF analysis of aberrantly hypermethylated regions revealed enrichment for binding sites of AP2a, AHR, HAIRY, ARNT, and HIF1 transcription factors, reflecting contributions of dysregulated hypoxia signaling pathways in RCC.
|
24916699 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to evaluate the significance of 3p loss (loss VHL gene) and 14q loss (loss HIF-1α gene) in clear cell renal cell carcinoma (ccRCC).
|
23335244 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis suggests that the substitution of C allele with T at HIF-1α gene C1772T polymorphism is a risk factor of cancer, especially for cervical, head and neck cancer, pancreatic cancer and renal cell carcinoma.
|
24367595 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hypoxia-inducible factor 1α mediates the down-regulation of superoxide dismutase 2 in von Hippel-Lindau deficient renal clear cell carcinoma.
|
23611775 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CPT demonstrated striking inhibition of both HIF-1α and HIF-2α accumulation in von Hippel-Lindau (VHL)-defective ccRCC cells, but surprisingly failed to inhibit protein levels of HIF-2α-dependent target genes (VEGF, PAI-1, ET-1, cyclin D1).
|
24136229 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and is often linked to loss of chromosome 3p, which harbors the VHL tumor suppressor gene, loss of chromosome 14q, which includes HIF1A, and gain of chromosome 5q.
|
24332042 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular modeling of the VHL-ElonginC-HIF-1alpha complex predicted that the p.Asn78Tyr amino acid exchange remarkably alters the 77-83 loop structure of VHL protein and destabilizes the VHL-HIF-1alpha complex suggesting that the mutation causes type I phenotype and has high risk to associate to renal cell carcinoma.
|
23298237 |
2013 |